secwatch.observer — SEC 8-K summary
======================================

Issuer:     SYNLOGIC, INC. (SYBX)
CIK:        0001527599
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0000950170-22-024119
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Synlogic Q3 net loss $17.9M; cash $91.7M; positive Phase 2 PKU data supports Phase 3 start in H1 2023
--------------------------------------------------------------------------------

- Cash, cash equivalents and short-term investments of $91.7M as of Sept 30, 2022; runway into 2024.
- Q3 revenue $0.7M (vs $0.9M Q3 2021) from Roche IBD collaboration; net loss $17.9M ($0.25/sh) vs $16.0M ($0.29/sh) prior year.
- R&D expense $14.6M, G&A $4.4M, both up from prior year period.
- Positive Phase 2 'Synpheny-1' top-line data for SYNB1934/SYNB1618 in PKU; Phase 3 registrational study planned H1 2023.
- Earned research milestone from Roche collaboration for IBD Synthetic Biotic candidate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527599/000095017022024119/0000950170-22-024119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527599/000095017022024119/sybx-20221110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer